Resolute Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Resolute Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-14,670	Closed	-$71.6K	–	77
2025 Q3	$71.6K	Hold	14,670	–	–	0.02%	73
2025 Q2	$74.2K	Buy	+14,670	New	+$72.1K	0.02%	68
2025 Q1	–	Sell	-14,670	Closed	-$99.2K	–	86
2024 Q4	$99.2K	Hold	14,670	–	–	0.02%	77
2024 Q3	$96.7K	Hold	14,670	–	–	0.02%	58
2024 Q2	$110K	Hold	14,670	–	–	0.03%	52
2024 Q1	$146K	Hold	14,670	–	–	0.03%	51
2023 Q4	$145K	Hold	14,670	–	–	0.02%	60
2023 Q3	$112K	Buy	14,670 +3,668	+33%	+$36.6K	0.02%	56
2023 Q2	$82.2K	Hold	11,002	–	–	0.01%	59
2023 Q1	$73.4K	Hold	11,002	–	–	0.01%	58
2022 Q4	$84.8K	Hold	11,002	–	–	0.01%	54
2022 Q3	$117K	Buy	11,002 +1,834	+20%	+$18.6K	0.01%	58
2022 Q2	$75K	Hold	9,168	–	–	0.01%	67
2022 Q1	$66K	Hold	9,168	–	–	﹤0.01%	74
2021 Q4	$157K	Buy	+9,168	New	+$173K	﹤0.01%	67

Other funds holding RXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Resolute Advisors's RXRX Position: Q4 2025 in Review

Resolute Advisors sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 14,670 shares — an estimated $71.6K sold.

Resolute Advisors first reported a position in RXRX in Q4 2021 and held it in 15 quarters. The position peaked at $157K in Q4 2021. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

Resolute Advisors reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Resolute Advisors sold 14,670 Recursion Pharmaceuticals shares in Q4 2025, an estimated $71.6K.
Resolute Advisors first reported a position in Recursion Pharmaceuticals in Q4 2021 and held it in 15 quarters.
Resolute Advisors's Recursion Pharmaceuticals position peaked at $157K in Q4 2021.
333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Resolute Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.